Polisseni 2013.

Methods	Randomised double‐blind controlled trial
Participants	174 postmenopausal women between 45 and 60 years of age with moderate or pronounced vasomotor symptoms and a Blatt–Kupperman menopausal index (BKMI) ≥ 20 points, with no treatment for menopausal symptoms in the past 6 months
Interventions	Tibolone 2.5 mg/d; 1 mg oestradiol + 0.5 mg norethindrone acetate; 50 mg calcium carbonate and 200 UI vitamin D3 (not considered in the meta‐analysis)
Outcomes	Vasomotor symptoms, insomnia (measured through the Women’s Health Questionnaire)
Notes	Trial location: Brazil (single centre) Follow‐up: 12 weeks Timing: June 2009 to June 2011
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated list of random numbers
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind trial; study authors declared that all capsules appeared identical
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	High risk	47 participants lost to follow‐up (with differential attrition among groups); only treated women appear to have been assessed
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	Low risk	Study authors declare that they have no conflicts of interest